Researchers at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), have found that ...

Researchers have developed a new oral drug that boosts metabolic activity in muscle rather than altering appetite like GLP-1 ...

FGF19 triggers the brain to burn more energy and activate fat-burning cells, offering a potential new path for obesity ...

Type 1 diabetes (also known as diabetes mellitus) is an autoimmune disease in which immune cells attack and destroy the insulin-producing cells of the pancreas. The loss of insulin leads to the ...

Resmetirom effectively resolves MASH and improves fibrosis, independent of GLP-1 or SGLT2 inhibitor use, in patients with T2DM. Achieving ≥5% weight loss enhances resmetirom's effects on MASH ...

Wang et al. examine the sex-specific associations of intrapancreatic fat deposition (IPFD) with incident type 2 diabetes (T2D) using the UK biobank cohort. IPFD is associated with incident T2D ...